Integrated Diagnostics Secures $10M for Clinical Feasibility Studies for Lung Cancer, AD Biomarkers
August 06, 2010
Integrated Diagnostics Secures $10M for Clinical Feasibility Studies for Lung Cancer, AD Biomarkers
The company next year plans to launch a 1,000-patient verification trial for its lung cancer protein biomarker panel, with trials for its Alzheimer's disease panel likely to follow, said an official.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Agilent Partners with Integrated Diagnostics, Further Signaling Focus on MRM-MS as Clinical Platform
January 13, 2012 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - Opko Health, Scripps Institute Developing Antibody-Based Alzheimer's Diagnostic
January 7, 2011 / ProteoMonitor - Integrated Diagnostics Secures Additional $10M to Prep for 2013 Launch of Lung Cancer Dx
February 24, 2012 / ProteoMonitor - Integrated Diagnostics Taking Aim at In Vivo Imaging, Therapeutics Markets with New PCC Reagents
October 28, 2011 / ProteoMonitor